Please assess the completion status of the following clinical trial:

Trial Title: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Age \>=18 years~* Histologically confirmed RCC with a clear-cell component~* Locally advanced or metastatic RCC~* At least one measurable lesion per RECIST 1.1 criteria, as determined by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI)~* No systemic therapy for advanced or metastatic RCC prior to enrollment~* Karnofsky Performance Status (KPS) ≥70~* Adequate baseline organ function~* A female was eligible to enter and participate in this study if she was of: non-childbearing potential, or negative serum pregnancy test with agreement to use adequate contraception during the study~* A male with female partner of childbearing potential must have vasectomy/agree to use effective contraception from 2 weeks prior to administration of the 1st dose of study treatment for a period of time after the last dose of study treatment~* Able to swallow and retain orally administered medication and must not have clinically significant GI abnormalities that may alter absorption~Additional inclusion criteria for starting everolimus:~* Disease progression must be within 6 months after stopping pazopanib~* At least one measurable lesion at the start of everolimus pe r RECIST 1.1 criteria, as determined by CT or MRI~* In case of central nervous system (CNS) progression or metastasis during pazopanib treatment: asymptomatic or neurologically stable, no requirement of steroids to control CNS symptoms, and no requirement of enzyme-inducing anticonvulsants within 4 weeks prior to the start of everolimus~Exclusion Criteria:~* Lactating female~* History of another malignancy (exception: patients disease-free for ≥3 years and patients with completely resected non-melanoma skin cancer or successfully treated in situ carcinoma)~* Symptomatic CNS metastases at baseline~* Clinically significant gastrointestinal abnormalities~* Moderate to severe hepatic impairment (Child Pugh Class C)~* Receiving chronic treatment with corticosteroids/other immunosuppressive agents~* Active bleeding, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)~* Corrected QT interval (QTc) \>480 msec using Bazett's formula~* Presence of any severe or uncontrolled medical conditions/infection~* Poorly controlled hypertension (defined as systolic blood pressure of \>=140mmHg or diastolic blood pressure of \>=90mmHg)~* History of cardiovascular disorders within the last 12 months (e.g. myocardial infraction or unstable angina), history of cerebrovascular events or pulmonary embolism within the last 6 months~* Active bleeding or bleeding susceptibility~* Known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that increased the risk of pulmonary hemorrhage~Additional criteria for exclusion from the second-line everolimus treatment period:~- The subject felt by the investigator to be unsuitable (on the basis of health, compliance, or for any other reason) for inclusion in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib followed by everolimus (Type: EXPERIMENTAL): First line pazopanib, followed by second line everolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy